LDRT

3

Review clinical trials related to LDRT. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer

There have been initial explorations on the treatment of peritoneal metastasis of gastric and colorectal cancer both at home and abroad. However, the comprehensive treatment plan of "LDRT + NIPEC + immunotherapy + systemic therapy" has not been reported either domestically or internationally. This study will explore the safety and efficacy of total abdominal low-dose radiotherapy followed by NIPEC and PD-1 treatment for peritoneal metastasis of gastric and colorectal cancer. 9-18 participants will be enrolled in this study. All will take part at Daping Hospital, Army Medical University.

Participants needed: 9
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityUpdated: Apr 27, 2026Locations: 2
Eligibility criteria

Age between18 and 75 years old. [+6]

Presence of distant metastasis other than peritoneal metastasis (ovarian metasta... [+9]

Status: Recruiting

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

In recent years, growing evidences have demonstrated promising synergistic antitumor effects of radiotherapy combined with immunotherapy. More over, LDRT may enhance the antitumor effect of immunotherapy by altering the tumor immune microenvironment (TIME) and adjusting the immune response. In this study, we will explore the safety and feasibility of LDRT and immunochemotherapy in liver metastatic colorectal cancer. 9-18 participants will be enrolled in this study. All will take part at Daping Hospital, Army Medical University.

Participants needed: 9
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityUpdated: Apr 3, 2026Locations: 2
Eligibility criteria

Age between18 and 75 years old. [+7]

Distant metastasis from other than the liver. [+8]

Status: Recruiting

LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study

To investigate the activating effect of local lesion low-dose radiotherapy (2Gy) on the tumor immune microenvironment, and the efficacy, safety, and feasibility of its combination with pembrolizumab and standard therapy in patients with advanced pancreatic cancer. Concurrently, to preliminarily establish an efficacy prediction model for the early identification of patient populations who would benefit from the treatment, thereby providing a theoretical foundation for the implementation of precision medicine.

Participants needed: 10
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Zhejiang Provincial People's HospitalUpdated: Jan 26, 2026Locations: 1
Eligibility criteria

Age ≥ 18 years, regardless of gender; [+5]

Previous history of radiotherapy; [+5]